| 摘要 |
<p>The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in Fig. 6B the mean +1- SEM serum 2,3-DHBA levels for the 12 ALS participants decreased signifacantly after pramipexole treatment.</p> |
